Form 4: Barinthus Biotherapeutics Director Anne Phillips Granted 20,174 Stock Options

Barinthus Biotherapeutics plc director Anne M. Phillips was granted 20,174 share options as part of her compensation, vesting based on continued service.

Summary

• Anne M. Phillips, a Director of Barinthus Biotherapeutics plc (BRNS), was granted 20,174 share options.
• The transaction date for this grant was June 10, 2025.
• Each share option has an exercise price of $1.00.
• The options are set to expire on June 10, 2035.
• The 20,174 shares underlying these options will vest in full on the earlier of June 10, 2026, or the date of the next annual meeting of shareholders of the Issuer.
• Vesting is contingent upon Ms. Phillips' continued service as a director through the applicable vesting date.
• The Ordinary Shares may be represented by American Depositary Shares (ADSs), with each ADS currently representing one Ordinary Share.

Sentiment

Score: 6

Explanation: The document reports a routine compensation event for a director, which is a neutral to slightly positive signal as it aligns management interests with shareholders. It does not contain information that would significantly alter the company's financial outlook or operations.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term value creation.
• Equity compensation is a standard practice for attracting and retaining qualified board members in the biotechnology industry.

Risks

• The options' value is dependent on the future stock price of Barinthus Biotherapeutics plc; if the stock price does not exceed the exercise price of $1.00, the options may expire worthless.
• Vesting of the options is subject to the director's continued service, meaning the options could be forfeited if service ceases before the vesting date.

Future Outlook

The future outlook for these options is tied to the director's continued service and the company's stock performance. The options are expected to vest fully by June 10, 2026, or the next annual shareholder meeting, provided the director remains in service.

Industry Context

The grant of stock options to directors is a common and widely accepted practice in the biotechnology and pharmaceutical industries. It serves as a key component of executive and director compensation packages, aiming to align the interests of leadership with long-term shareholder value creation, particularly in sectors with high R&D costs and long development cycles.

Comparison to Industry Standards

• The structure of this equity grant, including the vesting schedule tied to continued service, is consistent with typical director compensation practices observed across publicly traded biotechnology companies.
• The exercise price of $1.00, while specific to this grant, is a common feature of option grants, often set at or above the market price on the grant date to incentivize future stock appreciation.

Corporate Governance

Related Party Transactions

• The grant of 20,174 share options to Anne M. Phillips, a director of Barinthus Biotherapeutics plc, constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders by incentivizing an increase in the company's stock price.
• Employees: No direct impact on general employees is indicated by this specific filing.
• Management: The director receives equity compensation, which is a standard component of their remuneration package.

Next Steps

• The share options will vest in full on the earlier of June 10, 2026, or the next annual meeting of shareholders, subject to Anne M. Phillips' continued service as a director.
• Following vesting, Anne M. Phillips will have the right to exercise these options to acquire 20,174 Ordinary Shares (or ADSs) at the exercise price of $1.00 per share, up until the expiration date of June 10, 2035.

Key Dates

Keywords

Barinthus Biotherapeutics, BRNS, SEC Form 4, stock options, director compensation, equity grant, beneficial ownership, insider transaction